- Home
- TRVI vs CII Comparison
TRVI vs CII Comparison
Compare TRVI & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- CII
- Stock Information
- Founded
- TRVI 2011
- CII 2004
- Country
- TRVI United States
- CII United States
- Employees
- TRVI N/A
- CII N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- CII Investment Bankers/Brokers/Service
- Sector
- TRVI Health Care
- CII Finance
- Exchange
- TRVI Nasdaq
- CII Nasdaq
- Market Cap
- TRVI 725.7M
- CII 870.4M
- IPO Year
- TRVI 2019
- CII N/A
- Fundamental
- Price
- TRVI $7.42
- CII $22.06
- Analyst Decision
- TRVI Strong Buy
- CII
- Analyst Count
- TRVI 9
- CII 0
- Target Price
- TRVI $19.50
- CII N/A
- AVG Volume (30 Days)
- TRVI 1.8M
- CII 78.8K
- Earning Date
- TRVI 08-07-2025
- CII 01-01-0001
- Dividend Yield
- TRVI N/A
- CII 6.17%
- EPS Growth
- TRVI N/A
- CII N/A
- EPS
- TRVI N/A
- CII N/A
- Revenue
- TRVI N/A
- CII N/A
- Revenue This Year
- TRVI N/A
- CII N/A
- Revenue Next Year
- TRVI N/A
- CII N/A
- P/E Ratio
- TRVI N/A
- CII N/A
- Revenue Growth
- TRVI N/A
- CII N/A
- 52 Week Low
- TRVI $2.36
- CII $16.76
- 52 Week High
- TRVI $8.11
- CII $19.81
- Technical
- Relative Strength Index (RSI)
- TRVI 59.47
- CII 74.34
- Support Level
- TRVI $7.08
- CII $21.22
- Resistance Level
- TRVI $7.74
- CII $21.80
- Average True Range (ATR)
- TRVI 0.42
- CII 0.18
- MACD
- TRVI -0.05
- CII 0.04
- Stochastic Oscillator
- TRVI 55.77
- CII 89.62
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.